Aggressive Natalizumab Treatment For Jc Virus-Negative Relapsing-Remitting Multiple Sclerosis? Cost-Effectiveness Of First-Line Versus Second-Line Natalizumab Treatment

PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

Value in Health ◽

10.1016/s1098-3015(10)66969-0 ◽

2008 ◽

Vol 11 (6) ◽

pp. A602

Author(s):

MJ Nuijten ◽

T Mittendorf ◽

A Jäcker ◽

U Osowski

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2017.08.1948 ◽

2017 ◽

Vol 20 (9) ◽

pp. A723

Author(s):

L Ruiz ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

A Harrington

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Cost-Effectiveness of Subcutaneous Verse Intramuscular Interferon Beta-1A In Portugal Based on the Findings of Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.08.897 ◽

2014 ◽

Vol 17 (7) ◽

pp. A398

Author(s):

N. Silverio ◽

L. Sequeira ◽

D. Meletiche

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cochrane Collaboration ◽

First Line ◽

Relapsing Remitting ◽

Faculty Opinions recommendation of Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1145128.602265 ◽

2009 ◽

Author(s):

Dennis Bourdette ◽

Vijayshree Yadav

Keyword(s):

Multiple Sclerosis ◽

First Line ◽

Disease Modifying Therapy ◽

Relapsing Remitting ◽

Disease Modifying ◽

PNR1: COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF INTERFERON BETA-IB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN POLAND (2-YEARS PERSPECTIVE)

Value in Health ◽

10.1016/s1098-3015(11)70789-6 ◽

2000 ◽

Vol 3 (5) ◽

pp. 362-363

Author(s):

E Orlewska ◽

P Mierzejewski ◽

A Czlonkowska

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States

Value in Health ◽

10.1016/j.jval.2018.04.1400 ◽

2018 ◽

Vol 21 ◽

pp. S206

Author(s):

D Rao ◽

E Heidari ◽

KM Kamal ◽

AA Dashputre

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

The United States ◽

Relapsing Remitting ◽

Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis

Clinical Neuropharmacology ◽

10.1097/wnf.0000000000000305 ◽

2018 ◽

Vol 41 (6) ◽

pp. 199-201 ◽

Cited By ~ 1

Author(s):

Hussein Algahtani ◽

Bader Shirah ◽

Hind Abobaker ◽

Nebras Alghanaim ◽

Fatemah Kamel

Keyword(s):

Multiple Sclerosis ◽

Relapsing Remitting ◽

Natalizumab Treatment ◽

Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.481 ◽

2020 ◽

Vol 23 ◽

pp. 13-18 ◽

Cited By ~ 1

Author(s):

Pieralessandro Lasalvia ◽

Fabián Hernández ◽

Camilo Castañeda-Cardona ◽

J. Andrés Cuestas ◽

Diego Rosselli

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Multiple Sclerosis Treatment

Cost-Effectiveness Analysis of Cladribine Tablets for Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in Bulgaria

Value in Health ◽

10.1016/j.jval.2018.04.1403 ◽

2018 ◽

Vol 21 ◽

pp. S206 ◽

Cited By ~ 1

Author(s):

S Djambazov ◽

G Slavchev ◽

T Dineva ◽

P Panayotov ◽

T Vekov

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands

Applied Health Economics and Health Policy ◽

10.1007/s40258-019-00500-8 ◽

2019 ◽

Vol 17 (6) ◽

pp. 857-873 ◽

Cited By ~ 2

Author(s):

Renée Else Michels ◽

Maria de Fransesco ◽

Koshu Mahajan ◽

Gerald J. D. Hengstman ◽

Krijn M. H. Schiffers ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

The Netherlands ◽

Relapsing Remitting ◽